高级搜索
膀胱癌患者尿中可溶性Fas和可溶性FasL表达水平的意义[J]. 肿瘤防治研究, 2004, 31(05): 252-254. DOI: 10.3971/j.issn.1000-8578.2011
引用本文: 膀胱癌患者尿中可溶性Fas和可溶性FasL表达水平的意义[J]. 肿瘤防治研究, 2004, 31(05): 252-254. DOI: 10.3971/j.issn.1000-8578.2011
Clinical Value of Urine Soluble Fas and Soluble Fas Ligand in Bladder Cancer[J]. Cancer Research on Prevention and Treatment, 2004, 31(05): 252-254. DOI: 10.3971/j.issn.1000-8578.2011
Citation: Clinical Value of Urine Soluble Fas and Soluble Fas Ligand in Bladder Cancer[J]. Cancer Research on Prevention and Treatment, 2004, 31(05): 252-254. DOI: 10.3971/j.issn.1000-8578.2011

膀胱癌患者尿中可溶性Fas和可溶性FasL表达水平的意义

Clinical Value of Urine Soluble Fas and Soluble Fas Ligand in Bladder Cancer

  • 摘要: 目的 探讨可溶性Fas(sFas)和可溶性FasL(sFasL)在膀胱癌病人尿中的表达及其临床意义。方法 应用双抗体夹心ELISA法检测 4 3例膀胱癌病人术前、术后和 12例正常人尿中sFas和sFasL的表达水平。结果 膀胱癌病人尿sFas和sFasL水平均高于正常对照组, sFas与肿瘤临床分期、病理分级正相关, sFasL仅与肿瘤临床分期正相关。肿瘤切除术后sFas和sFasL水平均降低, 而且复发者术后sFas水平显著高于无复发者。结论 sFas和sFasL参与膀胱癌的发生、发展, 在一定程度上可以反映膀胱癌生物学行为。

     

    Abstract: Objective To examine the level of soluble Fas (sFas) and soluble Fas ligand (sFasL) in urine of patients with bladder cancer and to investigate their clinical value. Methods Enzyme linked immunosorbent assays (ELISA) was available to detect the level of sFas and sFasL in urine of 43 patients with bladder cancer and 12 cases of normal control. Results The urine level of sFas and sFasL in bladder cancer were significantly higher than those in normal control,respectively. Level of sFas was positive associatio...

     

/

返回文章
返回